Oragenics Announces Director Changes and New CMO

Ticker: OGEN · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1174940

Oragenics INC 8-K Filing Summary
FieldDetail
CompanyOragenics INC (OGEN)
Form Type8-K
Filed DateDec 16, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-election, officer-appointment

TL;DR

Oragenics swapped a director, added two new ones, and named a new Chief Medical Officer.

AI Summary

Oragenics, Inc. announced on December 11, 2024, several key events including the departure of director Dr. David G. Murdock, the election of new directors Dr. Michael J. McShane and Mr. David M. S. Johnson, and the appointment of Mr. David M. S. Johnson as Chief Medical Officer. The company also reported on compensatory arrangements for its officers and submitted matters to a vote of security holders.

Why It Matters

Changes in board composition and executive leadership can signal shifts in company strategy or operational focus, potentially impacting future performance and shareholder value.

Risk Assessment

Risk Level: medium — Changes in leadership and board composition can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

FAQ

Who has departed from the Oragenics board of directors?

Dr. David G. Murdock has departed from the Oragenics board of directors.

Who were elected as new directors to the Oragenics board?

Dr. Michael J. McShane and Mr. David M. S. Johnson were elected as new directors.

What new role has Mr. David M. S. Johnson taken on?

Mr. David M. S. Johnson has been appointed as the Chief Medical Officer.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is December 11, 2024.

What other items are covered in this 8-K filing besides director and officer changes?

This filing also covers compensatory arrangements of certain officers and the submission of matters to a vote of security holders.

Filing Stats: 953 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2024-12-16 16:10:26

Filing Documents

SIGNATURES

SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 16 th day of December, 2024. ORAGENICS, INC. (Registrant) BY: /s/Janet Huffman Janet Huffman Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing